Millennium Management LLC Makes New Investment in Dynavax Technologies Co. (NASDAQ:DVAX)

Millennium Management LLC bought a new position in Dynavax Technologies Co. (NASDAQ:DVAX) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 1,568,553 shares of the biopharmaceutical company’s stock, valued at approximately $17,615,000. Millennium Management LLC owned 1.20% of Dynavax Technologies at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in DVAX. Vanguard Group Inc. lifted its stake in Dynavax Technologies by 1.4% in the first quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock worth $116,682,000 after acquiring an additional 126,458 shares during the period. Kynam Capital Management LP lifted its position in shares of Dynavax Technologies by 180.0% in the 1st quarter. Kynam Capital Management LP now owns 4,239,780 shares of the biopharmaceutical company’s stock worth $52,616,000 after purchasing an additional 2,725,397 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Dynavax Technologies by 21.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,597,139 shares of the biopharmaceutical company’s stock worth $50,288,000 after purchasing an additional 644,428 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Dynavax Technologies by 2.2% during the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock valued at $27,830,000 after purchasing an additional 53,600 shares in the last quarter. Finally, Great Point Partners LLC increased its holdings in Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after buying an additional 1,109,080 shares during the period. Institutional investors own 96.96% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on DVAX. HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a report on Wednesday, August 7th. The Goldman Sachs Group decreased their price objective on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.67.

Dynavax Technologies Price Performance

Shares of DVAX opened at $11.02 on Friday. The company has a 50 day moving average of $11.08 and a two-hundred day moving average of $11.38. The company has a quick ratio of 13.18, a current ratio of 14.18 and a debt-to-equity ratio of 0.35. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $15.15. The company has a market cap of $1.44 billion, a price-to-earnings ratio of 183.67 and a beta of 1.37.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. The firm had revenue of $73.80 million during the quarter, compared to analyst estimates of $76.92 million. During the same quarter in the prior year, the business posted $0.03 EPS. As a group, analysts predict that Dynavax Technologies Co. will post 0.16 earnings per share for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.